215. ファロー四徴症 Tetralogy of Fallot Clinical trials / Disease details
臨床試験数 : 18 / 薬物数 : 26 - (DrugBank : 14) / 標的遺伝子数 : 13 - 標的パスウェイ数 : 45
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2013-002091-41-NL (EUCTR) | 09/10/2014 | 05/11/2013 | Research into the effect of the drug losartan in adult patients with a reduced function of the right cardiac chamber and a cardiac birth defect | Right vEntricular Dysfunction in tEtralogy of Fallot: INhibition of the rEnin-angiotensin-aldosterone system - Redefine trial | To study the effect of losartan in adult patients with Tetralogy of Fallot and right ventricular dysfunction, defined as right ventricular ejection fraction <50%. Without severe valvular lesions.;Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14] | Trade Name: Losartan Product Name: Losartan INN or Proposed INN: Losartan Potassium Other descriptive name: LOSARTAN POTASSIUM | Academisch medisch centrum | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | Netherlands | ||||
| 2 | NCT02010905 (ClinicalTrials.gov) | December 2013 | 6/12/2013 | Right Ventricular Dysfunction in Tetralogy of Fallot: Inhibition of the Renin-angiotensin-aldosterone System | Right Ventricular Dysfunction in Tetralogy of Fallot: Inhibition of the Renin-angiotensin-aldosterone System | Tetralogy of Fallot;Heart Defects, Congenital;Ventricular Dysfunction, Right | Drug: Losartan;Drug: Placebo | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | The Interuniversity Cardiology Institute of the Netherlands | Recruiting | 18 Years | 80 Years | Both | 120 | Phase 2 | Netherlands |